^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    NLRP3 inhibitor

    Related drugs:
    7d
    Oncolytic Reovirus-Induced Prostaglandin E2 Production in Human Tumor Cells. (PubMed, Biol Pharm Bull)
    A nuclear factor-kappa B (NF-κB) inhibitor, BAY11-7082, and a cyclooxygenase 2 (COX2) inhibitor, celecoxib, significantly inhibited PGE2 secretion, indicating that NF-κB and COX2 played a crucial role in reovirus-induced PGE2 production. These results indicate that reovirus replication in tumor cells is important for reovirus-induced PGE2 production. Attention should be paid to possible PGE2 production in tumors following reovirus treatment.
    Journal
    |
    CTSS (Cathepsin S)
    |
    Bay11-7082 • celecoxib oral
    16d
    Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus (clinicaltrials.gov)
    P2, N=162, Active, not recruiting, NodThera Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    17d
    SUN5 interacts with TRIM28, enhancing IκBα ubiquitination to promote glycolysis in colorectal cancer cells. (PubMed, Acta Biochim Biophys Sin (Shanghai))
    Mechanistically, SUN5 activates the NF-κB signaling pathway, which can be inhibited by the IKK inhibitor BAY11-7082...Moreover, xenograft transplantation experiments reveal that the knockdown of SUN5 inhibits glycolysis and tumorigenesis in vivo. Taken together, these findings indicate that SUN5 enhances the glycolysis and tumorigenesis of CRC cells via interaction with TRIM28, which provides a potential target for the diagnosis and treatment of CRC.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • NFKBIA (NFKB Inhibitor Alpha 2) • SLC2A1 (Solute Carrier Family 2 Member 1) • TRIM28 (Tripartite Motif Containing 28)
    |
    Bay11-7082
    19d
    Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS) (clinicaltrials.gov)
    P1, N=5, Not yet recruiting, Akros Pharma Inc.
    New P1 trial
    19d
    A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease. (clinicaltrials.gov)
    P1, N=29, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion
    1m
    Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity (clinicaltrials.gov)
    P2, N=176, Completed, Zomagen Biosciences Ltd. | Active, not recruiting --> Completed
    Trial completion
    2ms
    A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease (clinicaltrials.gov)
    P1/2, N=29, Terminated, Ventus Therapeutics U.S., Inc. | Recruiting --> Terminated; Sponsor decision
    Trial termination
    2ms
    Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) (clinicaltrials.gov)
    P2, N=80, Recruiting, NodThera Limited
    New P2 trial
    2ms
    SERENIA: A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. (clinicaltrials.gov)
    P2, N=124, Not yet recruiting, AstraZeneca
    New P2 trial
    2ms
    A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease. (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    2ms
    UNITE-ALS: Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis (clinicaltrials.gov)
    P2, N=240, Recruiting, Zydus Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    1,2,4-Trimethoxybenzene alleviates cognitive dysfunction in type 2 diabetes model rats by inhibiting NLRP3 inflammasome and restoring gut microbiota disorders. (PubMed, Biochem Pharmacol)
    Using a rat model of DCD induced by a high-carbohydrate and high-fat diet combined with streptozotocin (STZ), we evaluated the therapeutic effects of ZY16 and metformin on cognitive impairment in diabetic rats through the following measures: blood glucose levels, behavioral tests, biodiversity analysis of gut microbiota, and molecular and histological analyses...In conclusion, ZY16 plays a beneficial role in DCD by inhibiting NLRP3 inflammasome formation and restoring intestinal flora. This finding may contribute to the development of a novel intervention for the clinical management of DCD.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL18 (Interleukin 18) • NLRC5 (NLR Family CARD Domain Containing 5) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • CASP1 (Caspase 1)
    |
    metformin